The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of durvalumab (MEDI4736) immediately after completion of chemoradiotherapy in unresectable stage III non–small cell lung cancer: TORG1937 (DATE study).
 
Shinji Nakamichi
Honoraria - AstraZeneca; Bristol-Myers Squibb/Ono Pharmaceutical; Chugai Pharma; Merck; Taiho Pharmaceutical; Takeda
 
Kaoru Kubota
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; MSD Oncology; Nihonkayaku; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Toshihiro Misumi
Speakers' Bureau - AstraZeneca; Chugai Pharma
 
Shuji Murakami
Speakers' Bureau - AstraZeneca Japan; Chugai Pharma; Merck; MSD; Novartis; Ono Pharmaceutical
 
Tetsuro Kondo
Speakers' Bureau - Boehringer Ingelheim; MSD
 
Isamu Okamoto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD Oncology; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly Japan; Ono Pharmaceutical; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai/Roche (Inst); Daiichi Sankyo/UCB Japan (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Koichi Minato
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma
Research Funding - Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Daijiro Harada
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Company; Chugai Pharma; Lilly; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Taiho Pharmaceutical; Towa Pharmaceutical
Research Funding - AstraZeneca Japan; Bristol-Myers Squibb Company; Chugai Pharma; Kissei Pharmaceutical; Lilly; MSD K.K.; Novartis; Pfizer; Takeda
 
Kazutoshi Isobe
No Relationships to Disclose
 
Hidetoshi Itani
Honoraria - AstraZeneca; Chugai Pharma; Lilly Japan
Speakers' Bureau - Lilly Japan
Research Funding - Chugai Pharma (Inst)
 
Saori Takata
No Relationships to Disclose
 
Hiroshi Wakui
Speakers' Bureau - AstraZeneca; Chugai Pharma; Kyouwa Kirin; Lilly; MSD; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; UCB
 
Yuki Misumi
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Taiho Pharmaceutical (Inst)
 
Satoshi Ikeda
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca; Chugai Pharma
 
Tetsuhiko Asao
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Merck Serono; MSD K.K; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Nippon Boehringer Ingelheim
 
Takeo Inoue
No Relationships to Disclose
 
Shinobu Hosokawa
Speakers' Bureau - AstraZeneca Japan; Bristol Myers Squibb K.K.
 
Yumiko Kobayashi
No Relationships to Disclose
 
Yuichi Takiguchi
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Lilly; MSD Oncology; Taiho Pharmaceutical
 
Hiroaki Okamoto
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)